Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,079 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplantation, Renal Clear all
Active, not recruiting Not applicable Interventional

Virtually Supervised Exercise for Kidney Transplant Candidates

NCT05355545
View directory record Official record
Conditions
Physical Disability
Interventions
Virtually supervised exercise, Health education
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 19, 2026, 4:54 AM EDT
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients

NCT00308802
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney transplantation
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 19, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional Results available

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

NCT01436305
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation
Interventions
Alemtuzumab, MMF, Basiliximab, Short-term Tac, tacrolimus, Belatacept, methylprednisolone
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 19, 2026, 4:54 AM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 19, 2026, 4:54 AM EDT
Terminated Early Phase 1 Interventional Results available

Research Study of ATG and Rituximab in Renal Transplantation

NCT01318915
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
ATG, Rituximab, Tacrolimus, Sirolimus, MMF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 19, 2026, 4:54 AM EDT
Not listed Phase 4 Interventional

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

NCT00564538
View directory record Official record
Conditions
Liver Transplantation, Liver Disease, Immunosuppression
Interventions
anti-thymocyte globulin (rabbit), tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Sep 19, 2026, 4:54 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

NCT00097968
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2010 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 19, 2026, 4:54 AM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

NCT02723591
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, Tacrolimus immediate release
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

NCT00905515
View directory record Official record
Conditions
Kidney Transplantation
Interventions
cyclosporine, Prograf (Tacrolimus)
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 19, 2026, 4:54 AM EDT
Completed No phase listed Observational

Biomarkers of Aging as Predictors of Kidney Transplant Function

NCT02335333
View directory record Official record
Conditions
Delayed Graft Function, Other Complications of Kidney Transplant
Interventions
No treatment
Other
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 19, 2026, 4:54 AM EDT
Not listed Phase 4 Interventional

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

NCT04849533
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Belatacept, Everolimus, mycophenolate mofetil, corticosteroids, rabbit antithymocyte globulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Not applicable Interventional

Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment

NCT00714480
View directory record Official record
Conditions
Renal Transplantation, Immunosuppression
Interventions
anti-thymocyte globulin
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™

NCT04838288
View directory record Official record
Conditions
Renal Transplant
Interventions
Change from Prograf to Envarsus XR
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 4 Interventional Results available

Surgeon Infiltration QL Block Comparison

NCT03496610
View directory record Official record
Conditions
Quadratus Lumborum Block, Surgical Wound Infiltration
Interventions
Liposomal Bupivicaine, QL Block
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 19, 2026, 4:54 AM EDT
Completed No phase listed Observational

Studies of Kidney Transplant Outcome

NCT01277770
View directory record Official record
Conditions
Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections, Thymoglobulin
Interventions
Steroid-Free Maintenance Immunosuppression, Infection After Kidney Transplantation, Evaluation of the DGF nomogram in Thymoglobulin
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 19, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

Bariatric Surgery for ESRD Patients vs Control

NCT00580762
View directory record Official record
Conditions
Obesity, ESRD
Interventions
Roux-en-y gastric bypass (RYGB)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 19, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

NCT00262886
View directory record Official record
Conditions
Kidney Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 19, 2026, 4:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

NCT01163799
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alefacept (ASP0485)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 19, 2026, 4:54 AM EDT